A Pre-Active $8M: CIRM Backs Epicrispr's First-in-Human FSHD Study

Epicrispr Biotechnologies has been awarded an $8M grant from the California Institute for Regenerative Medicine to carry forward the first-in-human study of EPI-321 in facioscapulohumeral muscular dystrophy, or FSHD, the South San Francisco company announced on October 19, 2026.

The scope of the award is narrow by design. CIRM's award record identifies the project as the first-in-human EPI-321 trial and assigns it grant number CLIN2-20392, supported through the agency's Clinical Trial Stage Projects program. EPI-321 is intended to suppress inappropriate activity of DUX4, a gene implicated in progressive muscle damage. The study protocol describes an AAVrh74-delivered, noncutting epigenetic editor that targets the D4Z4 region associated with DUX4 regulation, aiming to quiet harmful gene activity without changing the underlying DNA sequence.

Two dates attach to the financing, and they are not the same event. CIRM's board approved the award on September 25, while Epicrispr publicized it on October 19. The agency's award database currently labels the grant pre-active, and the public record does not establish when cash reaches the company. Nor does the grant carry a verified valuation, an ownership change or a new venture syndicate; those blanks stay blank.

The clinical setting is specific. The ClinicalTrials.gov record for NCT06907875 describes a Phase 1/2, open-label, nonrandomized dose-escalation study with estimated enrollment of 12 patients across two dose cohorts. The primary outcome concerns adverse events, with other measures examining biological activity. Participants receive a single intravenous administration and are followed over an extended period, which is why a short treatment encounter generates a long investigation.

On October 5, Epicrispr reported increases in lean muscle volume and strength among the first six patients with six-month observations, compared against external natural-history data and modeled digital twins. Those are company-reported exploratory findings from an open-label, nonrandomized study, an evidentiary basis distinct from a randomized concurrent control group. The company expects twelve-month data from all study patients in the second half of 2027.

The grant sits alongside, rather than inside, Epicrispr's $90M Series C announced August 11, which was co-led by Octagon Capital and Janus Henderson Investors. The company said that financing would support EPI-321, additional programmable epigenetic medicines, its platform and manufacturing capabilities. The distinction is worth keeping: private investors can finance a platform, a pipeline and organizational capacity, while a grant directs support toward one particular investigation. Both forms of backing meet at EPI-321.

That candidate also gives Epicrispr a clinical setting in which to learn how its Gene Expression Modulation System behaves. According to the company's platform description, GEMS combines a DNA-binding component, a guide RNA and proteins that influence gene activity. Scientific founder Lei Stanley Qi helped develop tools for regulating gene expression, and CEO Amber Salzman leads the company as it carries that foundation into therapeutic development.